Nasdaq

bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS ...
Seeking Alpha

bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD

FDA approval of bluebird bio's Lyfgenia for SCD is significant, but high cost and black box warning present challenges. Despite revenue growth from Zynteglo and Skysona, bluebird bio struggles with ...
Business Wire

bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...
PharmiWeb

bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

Group C patients at six months post-treatment produced consistent median levels of gene therapy-derived anti-sickling hemoglobin (HbA T87Q) ranging from 44 – 59% (Month 6 – 21), reducing the median ...